Figure 10. DHS inhibits neuroblastoma tumor xenograft growth in mice.

(A) Experimental protocol for tumor development and DHS treatment. (B) Average tumor volumes. (C) Tumor images of different treatment groups. (D) Average tumor weights. SCID mice bearing IMR32 neuroblastoma tumors were orally administered with vehicle alone or DHS (25, 50 and 100 mg/kg, single dose/day, alternate day during 8-38^th day of experiments). The tumor volumes were measured on every alternate day, while the tumor weights were measured on the 38^th day. The photographs of the tumors were captured with a digital camera on the 38^th day of the experiments, and representative photographs are shown. (E) Organ histology. Heart, kidney and livers were removed on the 38^th day of above experiments, the organ sections were stained with hematoxylin-eosin and analyzed with a bright-field microscope. The experiments were repeated three times with similar results, and the values are mean ± S. E. M. ^*p<0.05 compared to vehicle-treated mice.